Oslo University Hospital: Myocardial Infarction trials
The registry lists 15 Myocardial Infarction studies with Oslo University Hospital as lead sponsor. 3 are open to participants now and 0 have results posted.
Phase 2 3Phase 3 1Phase 4 2No phase 9(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Norwegian Danish Spontaneous Coronary Artery Dissection Exercise StudyEnrolling by invitationNCT07785765Not applicable
- Norwegian Spontaneous Coronary Artery Dissection StudyRecruitingNCT07317323
- Predictors of Failed Thrombolysis in Acute Myocardial InfarctionRecruitingNCT05347732
- BEtablocker Treatment After Acute Myocardial Infarction in Patients Without Reduced Left Ventricular Systolic FunctionActive, not recruitingNCT03646357Phase 4
- ASSessing the Effect of Anti-IL-6 Treatment in Myocardial Infarction: The ASSAIL-MI TrialCompletedNCT03004703Phase 2
- One-hour Troponin in a Low-prevalence Population of Acute Coronary SyndromeCompletedNCT02983123
- Thrombus Aspiration in Acute ST-elevation Myocardial InfarctionCompletedNCT02746822
- Prospective Randomized Optical Coherence Tomography Oslo tRialTerminatedNCT02337348Not applicable
- Omega-3 Fatty Acids in Elderly Patients With Acute Myocardial InfarctionCompletedNCT01841944Not applicable
- Effect of the Interleukin-6 Receptor Antagonist Tocilizumab in Non-ST Elevation Myocardial InfarctionCompletedNCT01491074Phase 2
- A Structuralised Sick-leave Program Compared to Usual Care Sick Leave Management in Patients After an Acute Myocardial InfarctionStatus unknownNCT01108653Not applicable
- Postconditioning in ST-elevation Myocardial InfarctionCompletedNCT00922675Not applicable
- Effect of Intravenous Immunglobulin (IVIG) After Myocardial InfarctionCompletedNCT00430885Phase 3
- Levosimendan in Acute Heart Failure Following Acute Myocardial Infarction.CompletedNCT00324766Phase 4
- Autologous Stem Cell Transplantation in Acute Myocardial InfarctionCompletedNCT00199823Phase 2